Saltar al contenido principal
xMedica

NCT07326709ClinicalTrials.gov

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

A Randomized, Placebo-controlled, Double-blind Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

En reclutamientoAdmite participantes ahora, según el registro.
Contactar con este estudio

En resumen

The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518…

Fase 3770 participantes buscados117 centros27 países

Categorías

Registrado en 1 registro

Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.

La información del ensayo se muestra tal como la publicó el registro, en su idioma original.

¿Le interesa este estudio?

Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-01-08; recorded start 2026-03-24
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1147 other studies in this databaseCounted from the lead sponsor named in the record (Novartis Pharmaceuticals)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 41 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 770 participants (target), run at 117 sites, across 27 countries.

How this score is built
  • Enrolment28/40

    770 participants (target)

  • Site count19/25

    41 sites

  • Country count12/15

    9 countries

  • Planned duration9/10

    Planned over about 50 months

  • Sponsor scale10/10

    Novartis Pharmaceuticals has led 1,104 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Resumen

The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.

This study will have a variable double-blind treatment duration of up to 36 months. As part of the study design, not every participant will complete 36 months of treatment. The study consists of 3 periods: * Screening Period: A period of up to 42-days to assess participants eligibility * Double-blind Treatment Period: This period will have variable individual treatment duration, up to 36 months. The double-blind treatment period concludes when ≥50% patients complete Month 36. The maximum treatment duration for an individual participant is 36 months. * Safety Follow-up Period: A period consisting of one safety follow-up visit, conducted on site or by phone call, for all participants not continuing treatment in the separate open-label extension study or discontinuing early. The visit/phone call will take place 30 days after End of Study (EOS)

Afecciones

  • Huntington Disease

Elegibilidad

Elegibilidad
SexoTodos
Edades21 Years – 70 Years
Voluntarios sanosNo

Elegibilidad tal como figura en el registro

Inclusion Criteria: * Signed informed consents must be obtained prior to participation in the study * Ambulatory male or female participants between 21 to 70 years of age, inclusive, on the day of Informed Consent signature * Genetically confirmed HD diagnosis with a cytosine-adenine-guanine (CAG) repeat length of 40 or above. Participants must have prior genetic confirmation and known CAG repeat length obtained prior to screening. * Meets all of the following criteria: * UHDRS IS score ≥90 * UHDRS TFC score = 13 * UHDRS TMS score = 7-25, inclusive * CAP100 ≥ 70 Calculation: CAP = Age at study entry × (CAG length - 30) / 6.49 Exclusion Criteria: * History of gene therapy or cell transplantation or any other experimental brain surgery for the treatment of HD * Serologic evidence for active viral hepatitis as indicated by: * positive anti-HBc IgM * positive anti-HBc IgG confirmed by positive HBsAg and/or HBV DNA * positive HCV ab test confirmed by positive HCV RNA * Immunodeficiency diseases, including a positive human immunodeficiency virus (HIV) test result * History or current diagnosis of ECG or cardiac abnormalities indicating significant risk of safety for participants such as: * Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second- or third-degree AV block without a pacemaker * History of familial long QT syndrome or known family history of Torsade de Pointes * Women of childbearing potential, defined as all women physiologically capable of becoming pregnant from menarche until becoming post-menopausal, unless they have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral salpingectomy at least six weeks before taking study treatment. In the case of oophorectomy alone, the reproductive status of the woman needs to have been confirmed by follow-up hormone level assessment. o WOCBP are excluded unless they are using highly effective methods of contraception (failure rate \< 1% per year) while taking study treatment and for 8 months after stopping study treatment. * Pregnant or nursing (breastfeeding) women Other protocol defined inclusion/exclusion criteria may apply

Elegibilidad en frases sencillas

Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.

Diseño del estudio

Diseño del estudio
Tipo de estudioDe intervención
FaseFase 3
AsignaciónAleatorizado
Modelo de intervenciónPARALLEL
Propósito principalTREATMENT
EnmascaramientoQUADRUPLE (4)
Inscripción770 participantes buscados

Patrocinador y colaboradores

  • Novartis Pharmaceuticals Patrocinador

Grupos e intervenciones

  • VotoplamEXPERIMENTAL

    Votoplam (blinded) taken orally, randomized in a 3:2 ratio (Votoplam: Placebo)

  • PlaceboPLACEBO_COMPARATOR

    Placebo (blinded) taken orally, randomized in a 3:2 ratio (Votoplam: Placebo)

Intervenciones

  • Fármaco Placebo

    Placebo

  • Fármaco Votoplam (blinded)

    Votoplam (blinded) active treatment

Variables de resultado

  1. Variable de resultado principal

    Change from Baseline in cUHDRS score

    The Composite Unified Huntingtons Disease Ratings Scale (cUHDRS) is an improved composite measure to assess multi-domain clinical progression in HD. The cUHDRS is a combined weighted score of measures of motor function (TMS), cognition (SDMT and SWRT) and overall functional capacity (TFC): cUHDRS = \[(TFC-10.4)/1.9 - (TMS-29.7)/14.9 + (SDMT-28.4)/11.3 + (SWRT - 66.1)/20.1\] + 10. In conjunction with one another, these measures provide a comprehensive, sensitive and specific tool for monitoring disease progression, with lower scores indicating more severe disease. cUHDRS score range from -8 to 25.

    Plazo Baseline, Month 36

  2. Variable de resultado secundaria

    Change from Baseline in UHDRS-TFC

    The UHDRS-Total Functional Capacity (TFC) focuses on the Investigator's assessment of the participant's capacity to perform a range of activities including occupation, finances, self-care, domestic chores and activities of daily living. The responses are derived from interview with the participant and/or companion, if applicable. Scores range from 0 to 13, with higher scores representing better functioning.

    Plazo Baseline, Month 36

  3. Variable de resultado secundaria

    Change from Baseline in UHDRS-IS

    The UHDRS-Independence Scale (IS) measures a patient's overall level of functional independence in activities of daily living. It provides a single score ranging from 10 (total dependence/bedbound) to 100 (no special care needed) in intervals of 10, with higher scores indicating better functioning. Scores can also be assigned in increments of 5 for intermediate levels of function.

    Plazo Baseline, Month 36

  4. Variable de resultado secundaria

    The time to decline in TFC score by at least one or IS score by at least 10

    The UHDRS-Total Functional Capacity (TFC) focuses on the Investigator's assessment of the participant's capacity to perform a range of activities including occupation, finances, self-care, domestic chores and activities of daily living. The responses are derived from interview with the participant and/or companion, if applicable. Scores range from 0 to 13, with higher scores representing better functioning. The UHDRS-Independence Scale (IS) measures a patient's overall level of functional independence in activities of daily living. It provides a single score ranging from 10 (total dependence/bedbound) to 100 (no special care needed) in intervals of 10, with higher scores indicating better functioning. Scores can also be assigned in increments of 5 for intermediate levels of function.

    Plazo Baseline to end of treatment up to 36 months

  5. Variable de resultado secundaria

    Change from Baseline in UHDRS-TMS

    The UHDRS-Total Motor Score (TMS) is the cumulative sum of the individual motor ratings obtained during the administration of the motor assessment portion of the UHDRS. It includes items related to eye movements, speech, limb movements (including hand taps and pronation-supination), dystonia, chorea, and gait/balance. Scores range from 0 to 124, with higher scores indicating greater motor impairment.

    Plazo Baseline, Month 36

  6. Variable de resultado secundaria

    Change from Baseline in SDMT

    The Symbol Digit Modality Test (SDMT) is used to assess attention, working memory, psychomotor speed and visual perceptual processing. Participants are presented with a translation key of specific numbers paired with unique abstract symbols. Below the translation key is an array of symbols paired with empty spaces, the participant's task is to match the number for each symbol as quickly as possible in a given time frame. Scores are based on number of correctly paired items and range from 0 to 110, with higher scores representing better performance.

    Plazo Baseline, Month 36

  7. Variable de resultado secundaria

    Change from Baseline in SWRT

    The Stroop Word Reading Test (SWRT) is a measure of processing and psychomotor speed. Participants are presented with a list or words (color names) printed in black ink and asked to read aloud as many words as possible within a set timeframe. Scores are based on the number of words read correctly and range from 0 to 60, with higher scores representing better performance.

    Plazo Baseline, Month 36

  8. Variable de resultado secundaria

    Percent change from Baseline in blood mHTT protein

    The mutant huntington protein (mHTT) which is detectable both in blood and cerebrospinal fluid (CSF), represents a reliable biomarker for HD due to its direct involvement in disease pathology. Blood mHTT is a direct product of the pathogenic HTT gene mutation and represents a proximal marker of Huntington's disease (HD) biology.

    Plazo Baseline to steady state and up to 36 months in blood mHTT protein

  9. Variable de resultado secundaria

    Change from Baseline in serum NfL

    Serum Neurofilament light chain NfL is a component of the neuronal cytoskeleton, released into CSF and blood after neuro-axonal damage, serving as a marker of neurodegeneration and disease progression in HD.

    Plazo Baseline, Month 36

  10. Variable de resultado secundaria

    Incidence and severity of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and TEAEs leading to participant withdrawal

    Number of participants with AEs and SAEs, including notable findings on physical examination, changes in vital signs, laboratory parameters, ECG, etc.

    Plazo Baseline to up to 36 months

Fechas

Fechas
Fecha de inicio24 de marzo de 2026 (real)
Finalización principal2 de abril de 2030 (estimada)
Finalización30 de abril de 2030 (estimada)
Primera publicación8 de enero de 2026 (real)
Última actualización22 de septiembre de 2026
Resultados publicadosNo indicado en el registro
Estado verificado por última vezseptiembre de 2026

Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.

Ubicaciones

117 centros están en reclutamiento

Argentina

Argentina
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteBuenos AiresEn reclutamiento
Instituto Argentino de Investigación Neurológica (IADIN)CABABuenos AiresEn reclutamiento
Centro de Investigaciones Metabólicas (CINME)CABABuenos AiresEn reclutamiento
Novartis Investigative SiteCiudad deBuenos AiresEn reclutamiento

Australia

Australia
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteCaulfield SouthVictoriaEn reclutamiento
Novartis Investigative SiteWestmeadNew South WalesEn reclutamiento

Belgium

Belgium
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteLeuvenVlaams BrabantEn reclutamiento

Bulgaria

Bulgaria
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteSofiaEn reclutamiento
Novartis Investigative SiteSofiaEn reclutamiento

Canada

Canada
CentroCiudadEstado o regiónEstado
CUSM Montreal Neurological InstituteMontrealQuebecEn reclutamiento
Centre de recherche du CHUMMontrealQuebecEn reclutamiento
North York General HospitalNorth YorkOntarioEn reclutamiento

China

China
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteBeijingEn reclutamiento
Novartis Investigative SiteBeijingEn reclutamiento
The Second Xiangya Hospital of Central South UniversityChangshaHunanEn reclutamiento
West China Hospital of Sichuan UniChengduSichuanEn reclutamiento
Novartis Investigative SiteFuzhouFujianEn reclutamiento
Novartis Investigative SiteGuangzhouGuangdongEn reclutamiento
Novartis Investigative SiteGuangzhouGuangdongEn reclutamiento
The Second Affiliated Hosp Of Zhejiang Univ School Of MedicineHangzhouZhejiangEn reclutamiento
Novartis Investigative SiteShanghaiEn reclutamiento
Tongji Hos Affiliated Tongji Medical College of HuazhongWuhanHubeiEn reclutamiento

Colombia

Colombia
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteMedellínEn reclutamiento

Czechia

Czechia
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteBrnoEn reclutamiento
Novartis Investigative SitePragueEn reclutamiento

Denmark

Denmark
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteCopenhagenEn reclutamiento

France

France
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteAngersFranceEn reclutamiento
Novartis Investigative SiteMarseilleEn reclutamiento
Novartis Investigative SiteMontpellierEn reclutamiento

Germany

Germany
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteAachenEn reclutamiento
Novartis Investigative SiteBochumEn reclutamiento
Novartis Investigative SiteMünsterEn reclutamiento
Novartis Investigative SiteTübingenEn reclutamiento
Novartis Investigative SiteUlmEn reclutamiento

Hungary

Hungary
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteBudapestEn reclutamiento
Novartis Investigative SiteSzegedEn reclutamiento

Israel

Israel
CentroCiudadEstado o regiónEstado
Tel Aviv Sourasky Med Ctr IchilovTel AvivEn reclutamiento

Italy

Italy
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteBolognaBOEn reclutamiento
Novartis Investigative SiteBresciaBSEn reclutamiento
Novartis Investigative SiteMilanMIEn reclutamiento
Novartis Investigative SiteMilanMIEn reclutamiento

Japan

Japan
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteBunkyo KuTokyoEn reclutamiento
Novartis Investigative SiteKashiharaNaraEn reclutamiento
Novartis Investigative SiteSagamiharaKanagawaEn reclutamiento

Netherlands

Netherlands
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteLeidenSouth HollandEn reclutamiento
Novartis Investigative SiteMaastrichtLimburgEn reclutamiento

Poland

Poland
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteKrakowPOLEn reclutamiento

Portugal

Portugal
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteLisbonEn reclutamiento
Novartis Investigative SitePortoEn reclutamiento

Romania

Romania
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteBucharestEn reclutamiento

En el registro figuran 67 centros más.

Documentos del estudio

No hay documentos enlazados en este registro.

Cambios a lo largo del tiempo

  1. 22 de septiembre de 2026

    Centro añadido

    35 sites added (117 total)

    82117

  2. 31 de agosto de 2026

    Centro añadido

    22 sites added (82 total)

    6082

  3. 11 de agosto de 2026

    Centro añadido

    9 sites added (60 total)

    5160

  4. 29 de julio de 2026

    Centro añadido

    10 sites added (51 total)

    4151